Entero Healthcare Solutions Limited
Promoters PRABHAT AGRAWAL · PREM SETHI · ORBIMED ASIA III MAURITIUS LIMITED
Against an issue price of ₹1,258. Split- and bonus-adjusted official closes — a past move, never a forecast.
Entero Healthcare Solutions Limited raised ₹2,300 crore through a mainboard initial public offer.
The filing places it in Healthcare Equipment & Supplies and names three promoters: PRABHAT AGRAWAL, PREM SETHI and ORBIMED ASIA III MAURITIUS LIMITED.
The book was open from 9 February 2024 to 13 February 2024.
The issue was priced at ₹1,258 a share, from a band of ₹1,195 to ₹1,258.
Of the offer, ₹1,000 crore is a fresh issue of shares — money that goes to the company — and ₹600 crore is an offer for sale, which goes to existing shareholders selling down. Valued at the final issue price.
The issuer reported the offer subscribed 2.00 times the shares on offer. That is its own final figure, filed with the exchange after the book closed — not a reading we took while bidding was open.
The shares listed on 16 February 2024.
The last official close on file is ₹1,709 (30 September 2026), which is 35.8% above the issue price.
It now trades as ENTERO, and its filed financials are on its company page.
Shares sold in the issue at ₹1,258 last closed at ₹1,708.9.
See ENTERO’s filed financials and price history →Official exchange closes, restated for splits, bonuses and rights issues since listing. A record of past price movement, not a forecast.
Share counts converted at ₹1,258, the final issue price.
- How it was priced
- Book-built — the price was discovered inside a band from the bids received
- Listing sought at
- BSE And NSE
- Designated exchange
- BSE
- Discount
- ₹119 a share
- Registered office
- Northern India
- Company website
- www.enterohealthcare.com
- Registrar
- Link Intime India Private Limited
- Lead managers
- ICICI Securities Limited
- DAM Capital Advisors Limited (Formerly IDFC Securities Limited)
- Other LM / BRLM
- SBI Capital Markets Limited
- Jefferies India Private Limited
- Bidding opens9 Feb 2024
- Bidding closes13 Feb 2024
- Basis of allotmentnot published
Not published in the exchange feeds we ingest — we do not estimate it.
- Listing16 Feb 2024
This is the issuer’s own final figure, filed with the exchange once bidding had closed — not a reading we took while the book was open. The exchange publishes only a running cumulative figure and no history, so for an issue nobody polled live this filing is the only account of the book that exists. It covers the whole offer and carries no breakdown by category and no timestamp.
- Anchor investors44.8%56,94,753 sh
- Qualified institutional buyers40.5%51,57,217 sh
- Non-institutional investors3.2%4,05,878 sh
- Retail individual investors11.4%14,46,928 sh
- Reserved portion0.1%15,268 sh
No part of the offer was set aside for market maker or other.
The portion of the offer set aside for each category before bidding opened, as the issuer filed it. The anchor allocation is filed as its own line rather than inside the institutional one, so these add up to the whole offer. Shares as filed; the percentages are computed against the offer's own share count.
We did not poll this issue while its book was open. The exchange publishes only the current cumulative figure and no history, so a subscription series cannot be reconstructed after an issue closes.
We have not extracted an anchor allotment list for this issue.
- All other pre-issue capitalSEBI ICDR 2018 Reg. 17 — all other pre-issue capital, 6 months from allotment16 Aug 2024already free
- Promoters' minimum contributionSEBI ICDR 2018 Reg. 16(1)(a) — promoters' minimum contribution, 18 months from allotment16 Aug 2025already free
Computed from the SEBI ICDR 2018 lock-in rules, not disclosed by the issuer or the exchange. The regulation counts from the date of allotment, which no feed we ingest publishes, so these are counted from the listing date and fall at most two to three business days later than the true expiry.
Every offer document must set out the reasoning behind its own price: what the company earned in the years before it came to market, and what multiple of those earnings it is asking for. This is that chapter — the issuer’s argument for its price, not our assessment of it.
Figures as printed in the offer document's "Basis for Offer Price" chapter. A record of the case the issuer made for its own price, not our valuation of it.
Everything we extracted from this issue's offer document is the pricing justification rather than the restated statements — it is shown under how the offer was priced. The restated financial statements themselves have not been extracted for this issue.
We have not extracted this section from the offer document for this issue yet. It is read from the abridged prospectus, and several offer documents are served as .zip archives or as scanned pages with no text layer.
The offer document must name the listed companies the issuer considers comparable, and print their valuation figures beside its own. This is that list — the issuer’s choice of comparison, not ours.
| Company | P/E | P/B | RoNW | EPS | Income |
|---|---|---|---|---|---|
| Average Salesper Customernot in our universe | — | — | — | — | — |
| Employeesnot in our universe | — | — | — | — | — |
| Gross Profitnot in our universe | — | — | — | — | — |
| Medplus Health Services Limited | 177.2 | — | 3.4% | 4.17 | ₹46,037 cr |
| Revenue Growthnot in our universe | — | — | — | — | — |
| Warehouse Areanot in our universe | — | — | — | — | — |
| Warehousesnot in our universe | — | — | — | — | — |
The issuer's own figures as printed at the head of the same table — its claim about itself, on the same basis as its claims about the companies below.
Figures as PRINTED by the issuer in its own offer document. The comparison set is the issuer's choice, not ours.
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
DAM Capital Advisors Limited 2021 – 2026 | 31 6 measurable | +20.9% | 0 of 3 | 0 of 2 | 0 of 2 |
ICICI Securities Limited 2021 – 2026 | 87 13 measurable | +16.6% | 5 of 11 | 2 of 5 | 1 of 6 |
Jefferies India Private Limited 2022 – 2026 | 25 4 measurable | +21.1% | 2 of 5 | 1 of 1 | — |
SBI Capital Markets Limited 2022 – 2026 | 46 7 measurable | +4.5% | 4 of 6 | 0 of 1 | 0 of 2 |
| Firm | Issues | Typical listing move | Below issue @30d | @90d | @180d |
|---|---|---|---|---|---|
Link Intime India Private Limited 2021 – 2026 | 175 14 measurable | +10.2% | 3 of 13 | 1 of 9 | 0 of 5 |
A count of what happened to the other issues each firm was named on, computed from exchange closes. Not a rating, not a ranking, and not a view on the firm.
- Prospectus· PDF · exchange archive15 Feb 2024
- Draft red herring prospectus (DRHP)· PDF · exchange archive13 Sept 2023
- Listing filing (XBRL)· XML · exchange archive
- In-principle approval (XBRL)· XML · exchange archive
Filed with SEBI and the exchanges by the issuer. These are the source for every figure on this page.
Compiled from NSE and SEBI offer documents and exchange feeds. A description of the issue and of the bids received — not investment advice, and not a view on whether to apply. No grey-market premium, no allotment lookup and no listing-gain estimate is published here.